Pressure-based physiology is the gold standard
Optimizing PCI (O-PCI) is a series of educational meetings dedicated to helping cardiologists optimize decision-making in interventional cardiac procedures using state-of-the-art intravascular...
Optimizing PCI (O-PCI) is a series of educational meetings dedicated to helping cardiologists optimize decision-making in interventional cardiac procedures using state-of-the-art intravascular imaging and physiology technologies. Our renowned international faculty is committed to help cardiologists master interpretation of invasive diagnostic devices and treat with precision, thus securing optimal outcomes for patients.
Speakers
Dr. William Fearon
Speaker
Dr. William Fearon graduated from Dartmouth College and received his medical degree from Columbia... Dr. William Fearon graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow. He is currently a Professor of Cardiology and Director of Interventional Cardiology at Stanford University School of Mediciner. Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation. Dr. Fearon’s primary area of research interest is in coronary physiology. He was the US principal investigator and senior author of the FAME trial, published in the New England Journal of Medicine and was a co-principal investigator and senior author of the FAME 2 trial, also published in the New England Journal of Medicine. He is now the principal investigator of the international FAME 3 trial comparing bypass surgery to fractional flow reserve guided percutaneous coronary intervention. He serves on the editorial board of the Journal of the American College of Cardiology, Circulation, JACC Cardiovascular Interventions, and Circulation: Cardiovascular Interventions. He was the principal investigator on an R01 and is the PI on an R61/R33 NIH award evaluating cardiac allograft vasculopathy early after transplantation. Dr. Fearon’s clinical activities include not only percutaneous coronary intervention, but also transcatheter aortic valve replacement. He was a coauthor on the PARTNER 2A Trial published in the New England Journal of Medicine.
